sentibio.com (SNTI) Cash Funds per Single Share

Symbol and logo of brand Senti Biosciences (SNTI)

Can Senti Biosciences, Inc. (SNTI) overcome the liquidity deficit and the risk of trial failure in leukemia treatment? Robust patents on gene circuits and the support of US lobbyists serve as a defense. However, toxicity risks and ethical prohibitions remain relevant. Monitoring cash per share confirms that the 2.13 level represents the issuer's current measure of financial stability.

SNTI sentibio.com: Cash per Single Share in the range 04/28/2023 - 11/20/2026

Comprehensive metric breakdowns and analytics for sentibio.com (SNTI)

- market price and analyst price targets:
- cash and cash flow data:
Summary company analysis:SNTI (Senti Bio)
Finished products of Senti Biosciences, Inc.

Senti Biosciences, Inc. (SNTI) operates as an R&D startup that exists solely on raised capital prior to the commercialization of gene circuits. This model is quantified through the ratio of liquid assets to the number of shares outstanding. This metric determines the real value of the "safety cushion" per share, excluding unjustified market expectations. It is critical for investors to track the burn rate to assess the business's viability. By analyzing the amount of free cash per share, one can detect the depletion of reserves in a timely manner.